-

RayzeBio to Present at the 41st Annual J.P. Morgan Healthcare Conference on Monday, January 9, 2023

SAN DIEGO--(BUSINESS WIRE)--RayzeBio, Inc., a targeted radiopharmaceutical company developing an innovative pipeline against validated solid tumor targets, today announced that Ken Song, M.D., President and CEO of the Company, will be presenting at the 41st Annual J.P. Morgan Healthcare Conference on Monday, January 9, 2023.

J.P. Morgan Healthcare Conference
Date: Monday, January 9, 2023
Time: 2:00 p.m. - 2:25 p.m. PST
Location: The Westin St. Francis – Golden Gate Room

About RayzeBio

RayzeBio is a biotechnology company focused on improving outcomes for people with cancer by harnessing the power of targeted radioisotopes. With a focus on clinically validated solid tumor targets, RayzeBio is developing novel drug conjugates to deliver potent therapeutic radioisotopes such as Actinium-225, an alpha-emitter. The company is backed by a syndicate of sophisticated healthcare investors and was established in 2020. For additional information, please visit www.rayzebio.com.

Contacts

Arvind Kush
info@rayzebio.com

Industry:

RayzeBio, Inc.

Release Versions
English

Contacts

Arvind Kush
info@rayzebio.com

More News From RayzeBio, Inc.

RayzeBio, Inc. Announces Closing of Upsized $358 Million Initial Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares

SAN DIEGO--(BUSINESS WIRE)--RayzeBio, Inc. (Nasdaq: RYZB), a targeted radiopharmaceutical company developing an innovative pipeline against validated solid tumor targets, today announced the closing of its previously announced upsized $358 million initial public offering (IPO) of 19,869,240 shares of common stock, including the full exercise of the underwriters’ option to purchase up to 2,591,640 additional shares from RayzeBio, at a price to the public of $18.00 per share. RayzeBio sold 18,706...

RayzeBio, Inc. Announces Pricing of Upsized $311 Million Initial Public Offering

SAN DIEGO--(BUSINESS WIRE)--RayzeBio, Inc. (Nasdaq: RYZB), a targeted radiopharmaceutical company developing an innovative pipeline against validated solid tumor targets, today announced the pricing of its upsized $311 million initial public offering of 17,277,600 shares of common stock at a price to the public of $18.00 per share. RayzeBio is offering 16,114,600 shares of common stock and the selling stockholder named in the prospectus is offering 1,163,000 shares of common stock. RayzeBio wil...

RayzeBio Appoints Christy Oliger to its Board of Directors

SAN DIEGO--(BUSINESS WIRE)--RayzeBio, Inc., a targeted radiopharmaceutical company developing an innovative pipeline against validated solid tumor targets, appointed Christy Oliger to its board of directors. Ms. Oliger brings over 30 years of experience in the biopharmaceutical industry as a board member and executive, serving in various commercial and portfolio management roles at Genentech, Inc., Roche Holding AG and Schering-Plough Corporation. “I am very excited about the impact RayzeBio ca...
Back to Newsroom